ABERNETHY MATT — SEC insider filings
SEC reporting owner CIK 1724097. 27 insider filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2020-08-07 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 29 legs across 19 filings — 104,034 shares, $12,795,455 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: sale of 14,100 shares @ $150.38 ($2,120,347) in NEUROCRINE BIOSCIENCES INC, filed 2024-08-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Chief Financial Officer | 25 | — | 29 legs · 104,034 sh · $12,795,455 | 46 |
| FATE THERAPEUTICS INC (FATE) | Director | 2 | — | — | 2 |
Insider filings — ABERNETHY MATT
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 5,020 @ $0 · Tax withholding (F): 2,709 @ $156.22 · Sale (S): 2,311 @ $157.20 | EDGAR |
| 2026-06-15 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 87,900 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Gift (G): 2,249 @ $0 | EDGAR |
| 2026-02-17 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,133 @ $0 · Tax withholding (F): 1,151 @ $123.10 · Option exercise (M): 2,241 @ $0 · Tax withholding (F): 1,210 @ $124.12 · Option exercise (M): 2,566 @ $0 · Tax withholding (F): 1,385 @ $124.12 · +7 more | EDGAR |
| 2026-02-03 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,437 @ $0 · Tax withholding (F): 1,368 @ $136.06 · Option exercise (M): 2,437 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | FATE THERAPEUTICS INC (FATE) | Grant/award (A): 110,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,566 @ $0 · Sale (S): 1,352 @ $116.85 · Option exercise (M): 2,241 @ $0 · Sale (S): 1,206 @ $116.87 · Grant/award (A): 45,538 (derivative) @ $0 · Grant/award (A): 8,534 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-12 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,860 @ $0 · Sale (S): 980 @ $118.27 · Option exercise (M): 1,860 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,436 @ $0 · Sale (S): 1,283 @ $152.87 · Option exercise (M): 2,436 (derivative) @ $0 | EDGAR |
| 2024-08-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 14,100 @ $73.60 · Sale (S): 14,100 @ $150.38 · Option exercise (M): 14,100 (derivative) @ $0 | EDGAR |
| 2024-07-18 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 900 @ $73.60 · Sale (S): 900 @ $150.04 · Option exercise (M): 900 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 15,000 @ $73.60 · Sale (S): 15,000 @ $135.66 · Option exercise (M): 15,000 @ $73.60 · Sale (S): 15,000 @ $140.24 · Option exercise (M): 15,000 (derivative) @ $73.60 · Option exercise (M): 15,000 (derivative) @ $73.60 | EDGAR |
| 2024-02-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,352 @ $132.85 · Grant/award (A): 45,058 (derivative) @ $0 · Grant/award (A): 8,966 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,280 @ $142.19 · Sale (S): 980 @ $134.21 | EDGAR |
| 2024-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,283 @ $140.72 | EDGAR |
| 2023-08-23 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,132 @ $107.39 | EDGAR |
| 2023-02-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 63,789 (derivative) @ $0 · Grant/award (A): 10,264 (derivative) @ $0 | EDGAR |
| 2023-02-08 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,280 @ $105.67 · Sale (S): 2,030 @ $102.33 · Sale (S): 12,807 @ $102.42 · Sale (S): 11,491 @ $102.40 · Sale (S): 980 @ $104.19 | EDGAR |
| 2023-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,283 @ $109.98 | EDGAR |
| 2022-02-09 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,030 @ $80.80 · Sale (S): 1,280 @ $80.78 · Sale (S): 980 @ $79.65 | EDGAR |
| 2022-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 66,362 (derivative) @ $0 · Grant/award (A): 9,745 (derivative) @ $0 | EDGAR |
| 2021-12-03 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,645 @ $82.59 | EDGAR |
| 2021-03-26 | 4/A | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 49,049 (derivative) @ $0 | EDGAR |
| 2021-02-09 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 880 @ $116.85 · Sale (S): 2,030 @ $116.81 · Grant/award (A): 44,632 (derivative) @ $0 · Grant/award (A): 7,439 (derivative) @ $0 | EDGAR |
| 2020-12-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,645 @ $94.66 | EDGAR |
| 2020-11-16 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,257 @ $90.74 | EDGAR |
| 2020-08-07 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 2,257 @ $118.90 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1724097 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs